Shows
OncoPharmASCO '23 AppetizersASCO '23 Appetizers by John Bossaer2023-06-0811 minOncoPharmRibociclib-Tamoxifen: A Cautionary TaleRibociclib-Tamoxifen: A Cautionary Tale by John Bossaer2022-04-1410 min
OncoPharmBROCADE3After brief diatribes on PO azacitidine and COMBI-AD's 5-year non-OS analysis, we focus on BROCADE3 and the background on BRCA-mutated metastatic breast cancer treatment.
BROCADE3: https://doi.org/10.1016/S1470-2045(20)30447-22020-09-0316 minOncoPharmAlopeciaChemotherapy-induced alopecia is the next in our series on Foundational #OncoPharm topics.2020-08-2719 minOncoPharmATACOur Landmarks in #OncoPharm Series returns to discuss ATAC: Anastrozole or Tamoxifen Alone or in Combination for adjuvant breast cancer treatment.2020-08-2013 min
OncoPharmVIALE-A (venetoclax + azacitidine for elderly/unfit AML)VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity.
Link: https://doi.org/10.1056/nejmoa20129712020-08-1316 min
OncoPharmNew Anti-CD-19 And BCMA OptionsLots of new options for B-cell malignancies of all ages!
We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate).
Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.2020-08-0621 min
OncoPharmGemcitabineNext up in the Foundations of #OncoPharm series, gemcitabine.2020-07-3011 minOncoPharmAntiemetic & CIPN Guideline UpdatesWe summarize the changes to ASCO's latest Antiemetic Guidelines update as well as their guidelines for chemotherapy-induced peripheral neuropathy (CIPN).
Then, we take a look at the PO decitabine approval and ponder the question, does low albumin decrease tolerability to some TKIs?2020-07-2315 minOncoPharmConversation With A Breast Cancer SurvivorWe're joined by Dr. Karen Fancher, oncology pharmacist, to talk about her breast cancer story from diagnosis to shared-decision making treatment plans with her oncologist to treatment toxicity.2020-07-1634 minOncoPharmNeutropenic Fever 101While this is a topic best covered with case examples, we do our best to provide the basics in 20 minutes.
Experienced clinicians may not be aware of the How Long study briefly discussed in this episode: https://doi.org/10.1016/S2352-3026(17)30211-92020-07-0922 minOncoPharmEarly July FDA UpdatesFDA ended June with 5 new approvals.
*selinexor for r/r DLBCL
*pembrolizumab for cutaneous squamous cell carcinoma
*pembrolizumab for MSI-h/dMMR met. colorectal cancer
*avelumab maintenance for met. bladder cancer
*SC trastuzumab/pertuzumab/hyaluronidase2020-07-0213 minOncoPharmClinical Trial Endpoints in OncologyA primer on primary endpoints used in oncology clinical trials. Tailored for those new to in-depth evaluations of oncology literature.2020-06-2514 minOncoPharmLurbinectedin et alTopics on this week's Pod include:
-Lurbinectedin in SCLC
-Nivolumab is esophageal cancer
-Pembrolizumab for TMB-high cancers
-Gemtuzumab ozogamicin for pediatric AML
-Venetoclax + HMA for adult (unfit) AML
-Gardasil for prevention of SCCHN
-Perhaps the biggest non-oncopharm news of the year?2020-06-1818 minOncoPharmLD Vs LdLD Vs Ld by John Bossaer2020-06-1112 minOncoPharmASCO 2020Recapping lots of updates from ASCO 2020.
Then (20:00) we chat with Shannon Hough, oncology pharmacy specialist, to talk about her ASCO abstract (https://meetinglibrary.asco.org/record/185996/abstract) on pharmacist interventions in managing CINV.2020-06-0431 minOncoPharmMore NSCLC Updates (Checkmate-9La & ALTA-1L)Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC).
Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors.
(Lots of ASCO talk *next* week!)2020-05-2911 minOncoPharmNew Chemo - Free Immunotherapy Options For NSCLCThere are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape.
Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.2020-05-2116 minOncoPharmSelpercatinib & More!We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target.
Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30).
Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated cholangiocarcninoma.
RET fusions: https://doi.org/10.1016/j.ctrv.2019.101911
PAOLA-1: https://www.nejm.org/doi/full/10.1056/NEJMoa1911361
IMbrave150: https://www.nejm.org/doi/full/10.1056...2020-05-1429 minOncoPharmCapmatinib & SC DaratumumabFirst, we discuss the FDA approval of daratumumab hyaluronidase for subcutaneous administration and compare its administration to SC administration of rituximab hyaluronidase and trastuzumab hyaluronidase.
We end by discussing the 1st FDA-approved drug for MET exon 14 skipping mutations, capmatinib. We also discuss how a receptor tyrosine kinase could skip.2020-05-0816 minOncoPharmQ 6 Pembro, PARP Inhibitors, MonarcHER, GriffinTopics of discussion:
Q 6 week pembrolizumab dosing schedule FDA approved
Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28)
The monarcHER study of abemaciclib in HER+ MBC (12:20)
The GRIFFIN study of Dara+VRD in myeloma (17:00)2020-04-3025 minOncoPharmSacituzumab Govitecan, Tucatinib, And More!Five (5!) new #oncopharm products to discuss. First, sacituzumab govitecan. Then, (9:30) tucatinib. Finally, (18:40) mitomycin gel, pemitgatinib, and selumetinib.2020-04-2426 minOncoPharmJournal Club: Unscheduled Hydration in Patients Receiving HECOur 1st Journal Club.
1. Read this: https://www.futuremedicine.com/doi/10.2217/fon-2018-0787
2. Ask how, or if, this would change practice.
3. Listen.2020-04-1620 minOncoPharmBevacizumab's Wild Ride For Metastatic Breast CancerFirst, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer.
Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1).
Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs...
E2100: https://www.nejm.org/doi/full/10.1056/nejmoa072113
Avado: https://www.ncbi.nlm.nih.gov/pubmed/20498403
Ribbon-1: https://www.ncbi.nlm.nih.gov/pubmed/213832832020-04-0913 min
OncoPharmCaravaggioReviewing the lasted DOAC study in treating cancer-associated VTE: Caravaggio. We compare it the other major DOAC studies in this patient population. Caravaggio: https://www.nejm.org/doi/full/10.1056/NEJMoa1915103
Also, announcing our first journal club! This will be our 4/16 Pod. It is especially for an oncology APPE students missing out on an oncology experience, but all are welcome to participate. Journal Club link: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-07872020-04-0215 minOncoPharmBleomycinThe Foundations of OncoPharm series returns with a unique chemotherapy drug: bleomycin.
Also, Covid Thoughs (14:00).2020-03-2719 minOncoPharmRecent Landmarks (CLEOPATRA, Keynote189)Recent updated survival analyses for CLEOPATRA and Keynote-189 (6:45) require some historical context to truly see their impact. Finally, #AskOncoPharm returns (15:05) with a listener question about infusion rates when restarting daratumumab.2020-03-1918 minOncoPharm*Covid19 And Chemo*We all should do what we can to "flatten the curve" and that includes our patients on treatment. While there is no such thing as elective chemo, there are some practical ways we can minimize patients needing to come into our facilities.2020-03-1609 minOncoPharmViz-Aflibercept Pricing: A Case StudyLooking back at a 2012 NYT op-ed (https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html) that led to a 50% price decrease in a biologic cancer medication.2020-03-1208 minOncoPharmPre - HOPA News DunpA plethora of #oncopharm updates!
Isatuximab is approved and neratinib gets another breast cancer indication (2:00)
Pembrolizumab with chemo for triple-negative breast cancer (8:50)
New EPOC updated survival analysis on FOLFOX+cetuximab in isolated liver metastatic colon cancer (15:00)
Precision medicine in pancreatic cancer (19:30)
Cladribine + rituximab for hairy cell leukemia (23:30)2020-03-0529 minOncoPharmCYP2D6 & Tamoxifen UpdatesTwo recent publications add to our knowledge concerning the utility of CYP2D6 genotyping and tamoxifen.
TARGET-1: https://www.ncbi.nlm.nih.gov/pubmed/31821071
Tamoxifen D/C rates by 2D6 genotype: https://www.ncbi.nlm.nih.gov/pubmed/318003472020-02-2718 minOncoPharmCAR - NKYou've heard of CAR-T therapy, and now it's time to learn about CAR-NK cells.
Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa19106072020-02-1315 minOncoPharmNK - 1 Antagonist Drug InteractionsDrug-drug interactions are a key consideration when determining which NK-1 antagonist to use in patients receiving highly emetogenic chemotherapy. We discuss the issues for (fos)aprepitant, netupitant, & rolapitant.
A nice aprepitant review (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595939/) and the case for an aprepitant-vincristine interaction (https://doi.org/10.1177/1078155219870840).2020-02-0617 min
OncoPharmTazemetostatAll the need-to-know items about the latest #oncopharm approved drug, tazemetostat, to start the Pod. We end (9:15) with a brief discussion of how gut bacteria may lead to gemcitabine resistance.2020-01-3013 min
OncoPharmBendamustineFoundations of OncoPharm: Bendamustine2020-01-2317 min
OncoPharmAvapritinibNew Drug Update! We discuss the efficacy and safety data surrounding avapritinib's approval as well as its likely role in GIST management.2020-01-1616 min
OncoPharmSafety Signals & 6 - MP HepatotoxicityHow common are upon safety concerns from FDA on newly approved #oncopharm agents? Does the accelerated approval process lead to more safety updates? We discuss (https://doi.org/10.1634/theoncologist.2019-0653).
We also look at a possible way to mitigate 6-MP hepatoxicity (5:45) using allopurinol (https://doi.org/10.1080/10428194.2019.1702183).
Finally (10:55) we review the most recent FDA indications for olaparib and pembrolizumab.2020-01-0916 min
OncoPharmTrastuzumab DeruxtecanKicking off the 2020 Pod season with the last FDA-approval of 2019 - trastuzumab deruxtecan.2020-01-0213 min
OncoPharmEnfortumab-vedotin (& Asciminib)Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!2019-12-2616 min
OncoPharmArsenic SauceThe Foundations of #OncoPharm series combines with a thematic critique of an animated Holiday classic to examine the links between The Grinch and Arsenic Trioxide.2019-12-1915 minOncoPharmASH '19 UpdatesReviewing pertinent abstracts from ASH's 2019 annual meeting. Abstracts discussed: LBA-1 (blinatumomab), 2640 (venetoclax-azoles interactions), 2639 (FLAG/CLAG vs. CPX-351 in sAML), LBA-6/862/860 (myeloma), and 3310 (PK-targeted dosing of melphalan for autoHSCT). Search here: https://ash.confex.com/ash/2019/webprogram/start.html2019-12-1221 min
OncoPharmDose Dense ACThe Landmarks in #OncoPharm series returns with dose-dense AC, published in JCO in 2003 by Citron et al.
Link: https://www.ncbi.nlm.nih.gov/pubmed/126686512019-12-0517 min
OncoPharmCornucopia Of OncoPharm UpdatesThe menu: sirolimus vs. prednisone for standard risk aGVHD, levofloxacin prophylaxis in myeloma patients (9:00), acalabrutinib's approval for CLL/SLL (12:00), OS analysis from osimertinib's FLAURA (14:30), optimal sequencing of abiraterone & enzalutamide (23:20), some novel non-malignant heme drugs (26:45), outro music (30:00), 2 new drugs for sickle cell (30:30), pecan pie.2019-11-2735 min
OncoPharmZanubrutinibBTK-targeting therapy approved again! Zanubrutinib approved for Mantle Cell Lymphoma (2nd line) - how does it compare to ibrutinib and acalabrutinib?2019-11-2120 min
OncoPharmImmunotherapy InteractionsExamining the effects of antibiotics, corticosteroids (6:45), and cannabis (12:05) on immunotherapy effectiveness.2019-11-1415 min
OncoPharmData Dive Into NK-1 Antagonists & CarboplatinASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.2019-11-0717 min
OncoPharmCarboplatinThe basic must-know information for carboplatin, for students, residents, or anyone looking for a refresher.2019-10-3120 min
OncoPharmADAM VTE & Ibrutinib CV ToxicityADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.2019-10-2418 min
OncoPharmTo Rechallenge, Or Not To RechallengeWeighing the risks & benefits of immunotherapy rechallenge in patients with a prior immune-related adverse event (irAE). Reference: https://www.ncbi.nlm.nih.gov/pubmed/314613812019-10-1714 min
OncoPharmCASPIANReviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.2019-10-1011 min
OncoPharmESMO 2019Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.2019-10-0322 min
OncoPharmDanorubicin 90 mg/m2 (AML induction)The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.2019-09-2414 min
OncoPharmNew FDA approved indications for lenvatinib, pembro, and apalutamideDiscussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.2019-09-1916 min
OncoPharmCurious Case Of Ibrutinib On NetflixRecapping the NY Times (https://www.nytimes.com/interactive/2018/10/26/magazine/netflix-diagnosis-series-joe.html) & Netflix collaboration "Diagnosis" about a possible Ibrutinib ADR. We also the discuss the value of case reports for the #OncoPharm community.2019-09-1215 min
OncoPharmOncoPharm M & M Extreme Toxicity & PharmacogeneticsThe 2nd installment of the OncoPharm Morbidity & Mortality series discussed a published case report (https://www.ncbi.nlm.nih.gov/pubmed/28782406). We discuss the approach to take when a patient experiences unexpectedly extreme toxicity and the role pharmacogenetics may play. Suggested resource: https://cpicpgx.org2019-09-0513 min
OncoPharmIrinotecanThe Foundations of #OncoPharm series returns with all the must-know information for irinotecan.2019-08-2917 min
OncoPharmEntrectinib & FedratinibRunning through the drug information highlights of the latest approved #oncopharm agents: entrectinib and fedratinib.2019-08-2219 min
OncoPharmE1912: Ibrutinib/rituximab vs. FCR in CLLThis week we look at the NEJM publication earlier this month (https://www.nejm.org/doi/full/10.1056/NEJMoa1817073) of E1912. Points of discussion include IGHV mutational status, PFS vs. OS as endpoints in CLL, the benefit of rituximab in addition to ibrutinib, and ibrutinib toxicity in younger vs. older CLL patients.
(Also, apologies to my APPE student for dropping this Pod *after* your journal club on this paper.)2019-08-1519 min
OncoPharmASCO VTE Guidelines (& more!)Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients (1:15) and VTE treatment (12:50). Pembrolizumab's latest FDA-approval is discussed (16:00), as is pexidartinib's FDA-approval (18:00), and finally a comparison of BCOP pass rates by training status (22:34).2019-08-0826 min
OncoPharmDarolutamideDarolutamide has been FDA-approved. We discuss its differences and similarities to other 2nd-generation anti-androgens (enzalutamide & apalutamide) - especially potential drug interactions!2019-07-3116 min
OncoPharmAC - - > T (q week)Our Landmarks in #OncoPharm series returns to the breast cancer patient population to review the landmark 2008 NEJM article from Sparano et al (https://www.nejm.org/doi/full/10.1056/NEJMoa0707056) investigating the optimal taxane regimen to follow adjuvant AC.2019-07-2516 min
OncoPharmSelinexorA brief discussion on FDA's approval decision on selinexor and its possible role in therapy. Then, a more in-depth details on its MOA, dosing, and toxicity profile.2019-07-1815 min
OncoPharmPain Management In CancerAn overview of pain management principles in cancer patients. Topics covered include the role of NSAIDs, bisphosphonates, and opioids in treating or preventing pain. Also discussed: bowel regimens & opioid conversions.2019-07-1130 min
OncoPharmTamoxifenThe Foundations in #Oncopharm series returns with the story of a failed contraceptive candidate that became the first (?) targeted therapy for use in cancer. Tamoxifen's use, MOA, toxicities, and drug interactions are also discussed.2019-07-0320 min
OncoPharmAsk OncoPharm: Advice for PGY2 Oncology Pharmacy ResidentsWe open up the Ask #OncoPharm inbox to answer a listener question - What advice do you have before starting my PGY2 Oncology Pharmacy Residency?2019-06-2714 min
OncoPharmPembrolizumab Nets 2 More ApprovalsDiscussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)2019-06-2015 min
OncoPharmPolatuzumab-vedotinA newly approved drug for relapsed/refractory diffuse large B-cell lymphoma is discussed as well as PBR.2019-06-1313 min
OncoPharmASCO '19Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan.
*caveats apply2019-06-0618 min
OncoPharmAlpelisibDiscussing the 1st PI3-kinase inhibitor approved for a solid tumor, alpelisib for HR(+), HER2(-) metastatic breast cancer as 2nd line treatment. Worth sharing with her endocrine/DM colleagues...2019-05-3020 min
OncoPharmAC - - > T (q 3 week)The Landmarks in #OncoPharm continues down its breast cancer-centric track with the landmark CALGB 9344 trial that established the role of paclitaxel in the adjuvant setting --> https://ascopubs.org/doi/pdf/10.1200/JCO.2003.02.0632019-05-2313 min
OncoPharmAC (NSABP B-15)The Landmarks in #OncoPharm series returns with a discussion of NSABP B-15, which established AC as a standard adjuvant chemo regimen for breast cancer --> (https://ascopubs.org/doi/abs/10.1200/JCO.1990.8.9.1483)2019-05-2314 min
OncoPharmMay Approvals, More QuestionsRunning through updated FDA approvals from this month (ivosidenib, T-DM1, ramucirumab, avelumab/axitinib, & venetoclax/obinutuzumab) and how these approvals raise more questions.2019-05-1613 min
OncoPharmImatinibThe Foundations of OncoPharm returns with imatinib, the 1st TKI. Discussion includes its history (and how imatinib's Phase I study almost didn't happen), uses, and toxicity.2019-05-0919 min
OncoPharmUpdates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AMLDiscussion of 2 important malignant hematology updates: the NEJM publication of the 1st published results of CAR-T therapy in multiple myeloma and the FDA-approval of ivosidenib in frail AML patients (with IDH1 mutations).2019-05-0214 min
OncoPharmLenvatinib vs. Sorafenib (HCC)Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.2019-04-2411 min
OncoPharmErdafitinibSummary of erdafitinib's FDA-approval including dosing, MOA, toxicity, and (wait 'til the end) prevalence of FGFR mutations. Ifos. Eye-Phos.2019-04-1822 min
OncoPharmHOPA '19 ReflectionsReflections offered from HOPA's 2019 annual conference on cabozantinib, regorafenib, low-dose azacitidine, SC granisetron (this is a thing), clinical trial hope, and opportunities for students in HOPA2019-04-1114 min
OncoPharmOncoPharm M & M - Drug InteractionDebut of a new feature: OncoPharm M & M, where we'll discuss notable case reports of #oncopharm misadventures....how they happened...and how we can prevent them in the future. Our first installment in this series discusses a drug interaction between idelalisib & diazepam (Case Report Link: https://doi.org/10.1177%2F1078155216653705).2019-04-0211 min
OncoPharmEtoposideOur Foundations in #OncoPharm returns with etoposide, including a deeper than necessary discussion of the historical medical(?) uses of podophyllotoxins, its MOA, uses, and toxicities.2019-03-2817 min
OncoPharmUpdates: Venetoclax use in multiple myeloma, atezolizumab in small cell lung cancerThis week brought several notable updates we discuss: the FDA's concern with a venetoclax clinical trial in multiple myeloma patients, atezolizumab's expected FDA-approval for small cell lung cancer, and some neuro-oncology guideline endorsements.2019-03-2113 min
OncoPharmMetastatic Pancreatic CAncerBrief background on metastatic pancreatic cancer is provided, followed by a brief discussion of the main landmark clinical trials (and one not-so-landmark study) in this difficult disease state.2019-03-1414 min
OncoPharmS.C. Monoclonal AntibodiesComing to a P & T committee meeting near you....it's subcutaneous (S.C.) monoclonal antibodies. We discuss the two currently FDA-approved formulations: rituximab + hyaluronidase and trastuzumab + hyaluronidase.2019-03-0814 min
OncoPharmLessons Learned (from the last week)Providing some clinical pearls learned in the last week regarding patient education for ruxolitinib & alectinib. Then (11:50) we recap follow-up publications from Keynote-24 & the BRIGHT studies, before finishing up the week's journal scan with a discussion of the optimal dose of nivolumab + ipilimumab in melanoma and who may NOT benefit from palbociclib.2019-02-2823 min
OncoPharmAxitinib's Big WeekendAxitinib studies presented at ASCO-GU '19 with simultaneous NEJM publication are discussed, followed by a brief overview (18:50) of darolutamide, a new anti-androgen, and its drug interaction potential.2019-02-2123 min
OncoPharmIRISThe Landmarks in Oncology Pharmacy series returns to discuss the International Randomized Study of Interferon vs. STI571 (imatinib) aka IRIS.2019-02-1415 min
OncoPharmCannabidiol (CBD) & Potential Drug Interactions In Cancer PatientsCBD use is becoming more widespread in society, including in cancer patients. Potential, and significant, drug interaction concerns should be considered.2019-02-0714 min
OncoPharmMucositis & StomatitisMucositis & stomatitis are basically interchangeable terms for one of the hallmark chemotherapy toxicities. We discuss its pathophysiology, prevalent, and prevention/treatment.2019-01-3119 min
OncoPharmOlaratumab, Goodbye?Olaratumab received accelerated approval in 2016 under the condition a phase III study would confirm its benefit. It didn't. We explore some possible explanations why a seemingly promising drug for a tough disease hasn't panned out...2019-01-2418 min
OncoPharmConversation With An Osteosarcoma SurvivorIt's always enlightening to talk to a cancer survivor and is an essential part of the patient care process. This conversation touches on chemo-induced toxicities (e.g. ifosfamide neurotoxicity), supportive care advances (olanzapine!), and the anxiety of survivors live with while living scan-to-scan. Brought to you by the Bill Gatton College of Pharmacy.2019-01-1753 min
OncoPharmNew & Niche DrugsWe finish discussing the 2018 FDA-approvals (calaspargase, ravulizumab, tazgraxofusp).2019-01-1013 min
OncoPharmmFOLFIRINOXNew year, new chemo regimen to discuss. We go over mFOLFIRINOX for adjuvant pancreatic cancer from the recently published PRODIGE-24 study. We discuss out the regimen is modified, where to find dose reductions, and how many patients required G-CSF.2019-01-0316 min
OncoPharmLet's Talk About Mr. GowerKeeping it light this Holiday Season with a discussion of the portrayal of pharmacists, notably Mr. Gower from It's a Wonderful Life, in pop culture. Regular Pods return in 2019.2018-12-2007 min
OncoPharmFOLFOX (MOSAIC Trial)The Landmarks in Oncology Pharmacy series returns with a discussion of MOSAIC: FOLFOX adjuvant chemotherapy for stage ii & STAGE III colon cancer.2018-12-1320 min
OncoPharmGilteritinibAnother week, another FDA-approval for AML. We discuss the latest in #oncopharm approvals: the FLT3-inhibitor gilteritinib. For more background reading, try here: https://doi.org/10.1177%2F10781552188026202018-12-0517 min
OncoPharmElderly AML & LarotrectinibThe often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.2018-11-2726 min
OncoPharmRise (& Fall) Of ESAsDescribing the rationale for and rise in widespread ESA use for cancer patients going back 30 years....and why their use has been drastically curtailed in the last decade.2018-11-2122 min
OncoPharmCyclophosphamideDiscussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.2018-11-1518 min
OncoPharmLorlatinibReviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?2018-11-0624 min
OncoPharm2017 Was A Good Year2017 saw A LOT of #oncopharm approvals. Oncology pharmacist & educator John Bossaer runs through some of the most notable oncology pharmacy trends of the year, include CAR-T cell therapy2017-12-1823 minOncoPharmTales of Brave IressaDiscussion of gefitinib's journey back to the market and lessons to be learned from it by oncology pharmacist & educator John Bossaer.2017-11-3017 min